Monte Rosa Therapeutics Inc share price logo

Monte Rosa Therapeutics Inc Share Price

NASDAQ: GLUE

Small Cap

$14.71

-0.31

(-2.10%)

as on

Monte Rosa Therapeutics Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $14.20
    $14.92
    downward going graph

    3.47%

    Downside

    1.43%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.50
    $25.77
    downward going graph

    76.21%

    Downside

    75.19%

    Upside

    downward going graph

Monte Rosa Therapeutics Inc share price movements today

Previous Close
$15.03
Open
$14.75
Volume
1.6M
Day's Low - High
$14.20 - $14.92
52 Week Low - High
$3.50 - $25.77

Monte Rosa Therapeutics Inc Historical Returns

1 Month Return
-16.92 %
3 Month Return
-14.8 %
1 Year Return
+ 165.08 %
3 Year Return
+ 123 %
5 Year Return
0 %

Monte Rosa Therapeutics Inc Stock Fundamentals & Key Indicators

Check Monte Rosa Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-1.4524

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-45.9M

Revenue (TTM)

123.7M

Profit Margin

-31.23%

Return On Equity TTM

-16.94%

Monte Rosa Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Monte Rosa Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Monte Rosa Therapeutics Inc image
Monte Rosa Therapeutics Inc
BUY$1.3BNANA-31.23%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Stock Returns calculator for Monte Rosa Therapeutics Inc Stock including INR - Dollar returns

The Monte Rosa Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Monte Rosa Therapeutics Inc investment value today

Current value as on today

₹2,68,976

Returns

₹1,68,976

(+168.98%)

Returns from Monte Rosa Therapeutics Inc Stock

₹1,59,436 (+159.44%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Monte Rosa Therapeutics Inc Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Monte Rosa Therapeutics Inc. Average target price of $32.33

Monte Rosa Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Monte Rosa Therapeutics Inc.

What analysts predicted

54.5%UPSIDE

Target Price

$32.33

Current Price

$14.71

Analyzed by

14 Analysts

Target

$32.33

Monte Rosa Therapeutics Inc target price $32.33, a slight upside of 54.5% compared to current price of $14.71. According to 14 analysts rating.

Monte Rosa Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Monte Rosa Therapeutics Inc Stock has decreased by -37% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-37% versus previous 30 day period

Monte Rosa Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
8
1
4
9
60
84
23
12
2
Gross Profit
-1
-1
0
2
9
60
84
23
10
0
Operating Income
-36
-34
-34
-32
-26
13
44
-15
-32
-49
EBITDA
-35
-33
-33
-30
-24
15
46
-13
-28
-47
Interest Expense
-
0
-
-
-
-
-
-
-
-
Depreciation
1
1
1
2
2
2
2
2
2
2
Income Before Tax
-34
-33
-31
-30
-23
15
47
-11
-30
-46
Income Tax Expense
0
0
0
0
0
2
0
1
-3
0
Net Income
-34
-33
-31
-30
-23
13
46
-12
-27
-46
Net Profit Margin
0.00%
-379.94%
-3004.51%
-645.58%
-258.89%
22.16%
55.20%
-53.01%
-212.10%
-1658.94%

Monte Rosa Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
75
123
Gross Profit
0
0
-2
-8
-6
67
115
Operating Income
-7
-28
-72
-112
-143
-81
-54
EBITDA
-7
-27
-70
-108
-137
-72
-45
Interest Expense
0
0
1
3
-
-
-
Depreciation
0
0
2
3
5
8
8
Income Before Tax
-7
-35
-73
-108
-135
-70
-39
Income Tax Expense
0
0
-2
-3
0
2
-1
Net Income
-8
-35
-73
-108
-135
-72
-38
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
-96.14%
-31.23%

Monte Rosa Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-33
-31
-30
-23
13
46
-12
-27
-46
Operating Cash Flow
29
-38
-27
-20
128
-45
-34
100
-43
Investing Cash Flow
14
9
-61
37
-30
-100
25
38
-65
Financing Cash Flow
25
0
98
0
0
0
0
0
29
Change in Cash
69
-28
9
16
98
-145
-9
138
-78

Monte Rosa Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-35
-73
-108
-135
-72
-38
Operating Cash Flow
-23
-59
-92
-43
41
-22
Investing Cash Flow
-3
-9
-219
88
-44
-101
Financing Cash Flow
60
377
20
27
98
30
Change in Cash
32
308
-291
72
96
-94

Global Institutional Holdings in Monte Rosa Therapeutics Inc

Funds
Holdings
T. Rowe Price Associates, Inc.
6.08%
BlackRock Inc
5%
Geode Capital Management, LLC
1.51%
Alphabet Inc
1.92%
Geode Capital Management, LLC
1.58%
See all

Monte Rosa Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 15 September

    Mon, 08:59 PM

    -

    Monte Rosa announces collaboration with Novartis for novel degraders, receiving $120 million upfront and potential total payments of $5.7 billion.

Insights on Monte Rosa Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GLUE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLUE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, GLUE stock has moved up by 129.5%

About Monte Rosa Therapeutics Inc

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.
OrganisationMonte Rosa Therapeutics Inc
Headquarters321 Harrison Avenue, Boston, MA, United States, 02118
IndustryServices
CEODr. Markus Warmuth M.D.
E-voting on sharesClick here to vote

Key Management of Monte Rosa Therapeutics Inc

Name

Title

Mr. Filip Janku M.D., Ph.D.

Chief Medical Officer

Mr. Edmund Dunn C.P.A.

Senior VP & Corporate Controller

Mr. Magnus Walter DPHIL

Chief Technology Officer

Mr. Andrew Funderburk

Chief Investor Relations and Strategy Officer

Dr. Markus Warmuth M.D.

President, CEO & Director

Mr. Philip Nickson J.D., Ph.D.

Chief Business & Legal Officer

Dr. Sharon Townson Ph.D.

Chief Scientific Officer

Ms. Jennifer Champoux

Chief Operating Officer

Dr. John C. Castle Ph.D.

Chief Data & Information Officer

FAQs

What is Monte Rosa Therapeutics Inc share price today?

Monte Rosa Therapeutics Inc share price today is $14.71 as on at the close of the market. Monte Rosa Therapeutics Inc share today touched a day high of $14.92 and a low of $14.2.

What is the 52 week high and 52 week low for Monte Rosa Therapeutics Inc share?

Monte Rosa Therapeutics Inc share touched a 52 week high of $25.77 on and a 52 week low of $3.5 on . Monte Rosa Therapeutics Inc stock price today i.e. is closed at $14.71,which is 42.92% down from its 52 week high and 320.27% up from its 52 week low.

What is Monte Rosa Therapeutics Inc's market capitalisation today?

Monte Rosa Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Monte Rosa Therapeutics Inc Stock (GLUE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Monte Rosa Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Monte Rosa Therapeutics Inc Shares that will get you 0.1020 shares as per Monte Rosa Therapeutics Inc share price of $14.71 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Monte Rosa Therapeutics Inc Stock (GLUE) from India?

Indian investors can start investing in Monte Rosa Therapeutics Inc (GLUE) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Monte Rosa Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Monte Rosa Therapeutics Inc share’s latest price of $14.71 as on March 25, 2026 at 1:29 am IST, you will get 0.6798 shares of Monte Rosa Therapeutics Inc. Learn more about fractional shares .